Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.37 USD | -1.38% | -0.24% | -7.33% |
May. 16 | Transcript : Intra-Cellular Therapies, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM | |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.33% | 7.01B | D+ | ||
-2.00% | 90.27B | A- | ||
+1.32% | 40.12B | A- | ||
-15.73% | 31.75B | B- | ||
+63.18% | 26.6B | A | ||
-21.28% | 14.41B | C | ||
-8.50% | 12.92B | B- | ||
-44.07% | 11.3B | B | ||
-13.06% | 11.44B | D+ | ||
+5.17% | 8.87B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ITCI Stock
- Ratings Intra-Cellular Therapies, Inc.